Medicine
| ISSN | 22135383 |
|---|---|
| Country | United Kingdom |
| Publisher | Elsevier BV |
| Subject Areas | Medicine |
| Publication Type | Journals |
| Active Years | 2013-2021 |
| Website | Visit journal |
| JIF 2022–2023 | 2.000 |
The Journal of Cancer Policy is an international journal which publishes research and reviews on global cancer policy. The journal encompasses all aspects of cancer policy from prevention and public health through all modalities of control and cure palliative care and survivorship including Cancer systems and services research Cancer economics and valuebased care Inequalities in access and outcomes of cancer care Development and regulatory issues related to cancer drugs radiotherapy and surgical technologies Priorities for cancer policy development in low middle and high income countries Innovative strategies for prevention screening and diagnosis of cancer Development of cancer research and education infrastructure Social determinants of cancer The role of trade globalisation and the law in cancer control The role of the media and patient advocacy in cancer policy Policy and social science research germane to cancer Patient advocacy and information research.
| Year | 2-Year IF | 3-Year IF | 4-Year IF |
|---|---|---|---|
| 2023 | 1.845 | 1.542 | 1.465 |
| 2022 | 1.178 | 1.142 | 1.284 |
| 2021 | 1.159 | 1.304 | 1.220 |
| 2020 | 0.987 | 1.106 | 1.041 |
| 2019 | 1.212 | 1.178 | 1.283 |
| 2018 | 0.795 | 0.969 | 1.136 |
| 2017 | 0.667 | 0.935 | 1.099 |
| 2016 | 1.108 | 1.391 | 1.391 |
| 2015 | 1.783 | 1.783 | 1.783 |
| 2014 | 1.333 | — | — |
Note: impact factor data for reference only.
SJR measures scientific influence, weighting citations by the prestige of the citing journal.
| Year | SJR Score |
|---|---|
| 2023 | 0.819 |
| 2022 | 0.576 |
| 2021 | 0.350 |
| 2020 | 0.563 |
| 2019 | 0.612 |
| 2018 | 0.631 |
| 2017 | 0.459 |
| 2016 | 1.155 |
| 2015 | 0.891 |
The H-Index measures both the productivity and citation impact of a journal's publications.
| Year | H-Index |
|---|---|
| 2023 | 20.000 |
| 2022 | 18.000 |
| 2021 | 17.000 |
https://www.editorialmanager.com/cancerpolicy/default.aspx